NR 566 / NR566 Advanced Pharmacology Care of the Family Midterm Review| LATEST 2021 /2022 | Chamberlain College

Document Content and Description Below

NR 566 / NR566 Advanced Pharmacology Care of the Family Midterm Review| LATEST 2021 /2022 | Chamberlain College 1. How to measure therapeutic effect of HIV therapy - RNA LEVELS o baseline o 2... -4 weeks, no later than 8 weeks o every 4-8 weeks until suppressed o after suppressed every 3-4 months - Long-term virologic suppression x2 years o every 6 months - any change in status = chemo/steroids o every 3 months 2. Protease Inhibitor (PIs) Lopinavir - high risk patients - ORAL solution: Contraindicated for full-term infants (until 14 days after birth) and premature (until 14 days after due date) o cardiac disease o Hx prolong QT 3. Protease Inhibitor (PIs) Lopinavir - Lifespan considerations - Children: Safe after 14 days old - Pregnancy: approved w/ higher risks 4. Protease Inhibitor (PIs) Lopinavir/ritonavir - adverse effects - - QT prolongation 5. Protease Inhibitor (PIs) Saquinavir - Lifespan considerations - Children o Not identified as safe/efficient in children younger than 16 - Pregnancy o Safest PI for pregnancy - HIV treatment is recommended in pregnancy 6. Protease Inhibitor (PIs) Saquinavir - adverse reactions - - QT prolongation 7. Nucleoside/nucleotide Reverse Transcriptase Inhibitor (NRTIs). Didanosine (ddI) - high risk patient - Increase risk of pancreatitis with alcohol use, pancreatitis, and IV pentamide 8. Nucleoside/nucleotide Reverse Transcriptase Inhibitor (NRTIs). Didanosine (ddI) - Lifespan considerations - Children o approved in 6 years + weighing 20kg - Pregnancy o Less risk 9. Nucleoside/nucleotide Reverse Transcriptase Inhibitor (NRTIs). Zidovudine - Lifespan consideration - Children o neonates - Pregnancy o increased risk 10. Nucleoside/nucleotide Reverse Transcriptase Inhibitor (NRTIs): Zidovudine - high risk patients - Hx of o granulocytosis o low H&H o low vit B12 o low folic acid o current use of meds that cause myelosuppe 11. How to measure therapeutic effect of HIV therapy - CD4 counts o w/ suppressed RNA levels = increase CD4 levels - Check levels o baseline o at 3 month mark o during 1st 2 years every 3-6 months during therapy o long-term suppression - CD4 <300 = every 3-6 months [Show More]

Last updated: 1 month ago

Preview 1 out of 20 pages